Conventional phase II clinical trials use either a single-or multi-arm comparison scheme to examine the therapeutic effects of the experimental drug. Both single-and multi-arm evaluations have their own merits; for example, single-arm phase II trials are easy to conduct and often require a smaller sample size, while multiarm trials are randomized and typically lead to a more objective comparison. To bridge the single-and double-arm schemes in one trial, we propose a two-stage design, in which the first stage takes a single-arm comparison of the experimental drug with the standard response rate (no concurrent treatment) and the second stage imposes a two-arm comparison by adding an active control arm. The design is calibrated using a new concept, the detectable treatment difference, to balance the trade-offs between futility termination, power, and sample size. We conduct extensive simulation studies to examine the operating characteristics of the proposed method and provide an illustrative example of our design.
Introduction
In new drug development, phase II trials are typically called the stage of the proof of concept, which mainly focuses on the evaluation of the new agent's therapeutic effects. In particular, phase II trials aim to screen out nonpromising drugs and carry the promising ones forward to confirmative phase III trials. Typically, phase II trial designs use either a single-or two-arm comparison scheme.
Both single-and multi-arm evaluations have their own merits, hence they are implemented according to the practical situations. For instance, in cases when there is no existing standard therapy for comparison, and the placebo control might not be feasible due to ethical consideration of patients' worsening condition, it is rational to conduct a single-arm phase II trial. As there is no concurrent treatment group and thus no randomization is involved in a single-arm trial, the trial conduct is more straightforward and hypothesis testing can be easily established under a one-sample test framework. Nevertheless, the reality reveals that a large number of seemingly promising drugs that have shown potential efficacious effects in phase II trials fail eventually. One of the main reasons for such a high failure rate is that the experimental drug is merely compared with the standard response rate or historical data in a single-arm phase II trial, for example, using Simon's two-stage design. 1 Although single-arm trials are inherently comparative, they are less objective and can be biased due to existing differences between current and previous studies, such as patient populations, study criteria, and medical facilities. To overcome these issues, randomized two-arm phase II trials are often preferred when the standard of care is available. Nevertheless, randomized trials are more complicated and typically require a larger sample size.
Phase II trials can be further classified into single-arm phase IIa and randomized phase IIb studies: the former mainly monitors the safety of the drug and study its efficacy from an exploratory view, whereas the latter aims to more objectively assess the treatment improvement when compared against the standard of care. Usually, phase IIa and phase IIb are conducted as separate trials with a period of gap time between them. More specifically, let p S and p E denote the true response rates of the standard treatment and the experimental treatment, respectively. The single-arm study aims at testing hypotheses H 0 : p E p null versus H 1 : p E 4 p null þ where p null is the ''clinically uninteresting'' reference rate and is the treatment difference to be detected. 1, 2 In practice, the value of p null is often specified as the estimated response rate of the standard treatment. As the ultimate goal is to compare the treatment effect of the experimental drug with that of the standard, such a singlearm design is often inadequate to fulfill this purpose due to the variability and uncertainty of the standard response rate. Therefore, prior to moving the experimental drug to a large-scale phase III study, a randomized two-arm trial of a relatively small scale may be carried out subsequent to the single-arm study in order to make a more objective comparison.
A recent two-stage metastatic pancreatic cancer trial investigated the combination of gemcitabine and a Hedgehog pathway inhibitor in comparison with gemcitabine and placebo. 3 In stage 1, all patients were treated by the open-label Hedgehog inhibitor together with the standard-dose intravenous therapy gemcitabine, where both toxicity and efficacy were monitored. If the investigational drug could be well tolerated and showed certain activity, the trial would move to the phase II portion with two-arm randomization for further comparison. The pancreatic cancer trial had a lead-in single-arm stage with all patients treated by the new therapy, and then a randomized two-arm stage to compare with the standard therapy. The lead-in phase enrolled seven patients and the randomized phase allocated 53 patients to each arm. The trial recorded outcomes of overall response rates in percentage, and overall and progression-free survival in months. The design only counted in the outcomes in the second stage for a final frequentist comparison between the two treatments, rather than utilizing the data from both the lead-in single-arm stage and the randomized two-arm stage. To fully utilize the advantages of such singleand multi-arm comparison schemes, we propose a two-stage single-to-double arm design for phase II clinical trials. One of the main advantages of combining the phase IIa and phase IIb in one single trial versus two separate trials is the tremendous saving in time. In the single-to-double arm design, stage 1 performs a single-arm comparison of the experimental drug with the standard response rate (no concurrent treatment), and stage 2 conducts a two-arm randomized study to compare the experimental drug with the standard of care. Rather than using a single specified value p null for the standard response rate, we propose to adopt a prior distribution for p S , which is either derived from historical data or elicited from clinicians' belief, and we center the mean of the prior distribution at p null . At the end of stage 1, a futility stopping rule is applied to decide whether the trial should proceed into stage 2, where data from both stages are used for a final decision. Not only does such a seamless design eliminate the time gap between the conventional phase IIa and phase IIb trials, it also helps to pool information together from separate trials for more comprehensive decision making.
The single-arm stage of our design adopts a Bayesian approach to assessing the responses in the experimental arm, which is similar to various existing Bayesian designs for phase II single-arm trials. For example, Thall and Simon 4 provided useful guidelines by continuously monitoring every trial participant's outcome using posterior probabilities, and Lee and Liu 5 developed Bayesian predictive probability monitoring rules. Tan and Machin   6 studied a Bayesian two-stage phase II clinical trial design based on the posterior distribution of the response rate.
As an extension, Mayo and Gajewski 7 adapted the sample size calculation to include informative prior distributions. The double-arm stage of our design uses a prior distribution to account for the uncertainty of the standard response rate. Thall and Simon 8 discussed the importance of correctly modeling the variability of the standard response rate from historical data in the planning of phase II trials. Sambucini 9 assumed different priors for the standard response rate and compared the operating characteristics of a single-arm trial with a randomized trial based on these priors. Cellamare and Sambucini 10 developed a randomized two-stage design using a Bayesian predictive approach.
Our proposed design is in a similar spirit to various seamless phase II/III designs as it has the elements of a seamless transition from one stage to the other, as well as the pooling of data from both stages for a final decision. Bauer and Kieser 11 developed an adaptive design that can integrate the identification of promising treatments from multiple arms and the inference on the selected treatments. Liu and Pledger 12 proposed a two-stage design that adaptively establishes the dose-response relationship and selects the lowest effective dose among multiple doses while accounting for both safety and efficacy concerns. Simon, Wittes, and Ellenberg 13 proposed methods of treatment selection in randomized phase II trials. Storer 14 incorporated a hypothesis test on the response rate of the experimental arm in a randomized phase III trial. Inoue et al. 15 developed a seamless design that relates a phase II discrete endpoint with a phase III survival endpoint. Lai et al. 16 proposed jointly modeling and seamlessly expanding a randomized phase II study of response rates to a randomized phase III study of survival times.
Our seamless single-to-double arm design takes into account the trade-offs between futility termination, power, and sample size. First, the futility stopping rule is derived using a Bayesian approach that accounts for the prior information of p S . Second, the sample size is chosen to ensure the robustness of power, because a single-to-double arm design tends to suffer from power loss due to the uncertainty on p S . Traditionally, power calculation hinges upon specification of p S ¼ p null and p E ¼ p null þ under the alternative hypothesis, where denotes the treatment difference to be detected. As a result, power is maintained at the desired 1 À only when p S and p E take exactly the prespecified values. When the true response rates deviate from the prespecifications, the design could be either underpowered or overpowered. We show that for a single-to-double arm design, power changes asymmetrically: the closer the value of p S is to zero, the more severe is the power loss. Therefore, when the single-arm and doublearm phases are combined together, it would be unrobust to use the traditional approach that can only maintain power at a prespecified value of p S . To maintain the robustness of power, we use a beta prior distribution for p S in controlling some specific percentile of power. Third, the design parameters are calibrated to minimize the average sample number (ASN), which is defined as the average of the expected sample sizes under the null and alternative.
The rest of the article is organized as follows. In Section 2, we introduce the two-stage single-to-double design, which is centered around a new concept, the detectable treatment difference. In Section 3, we conduct extensive simulation studies to evaluate the performance of the proposed method and, in particular, show the interplay between power and sample size adjustment. In Section 4, we present a trial example to illustrate the proposed single-to-double design, and Section 5 concludes with some remarks.
Proposed design
To inherit the advantages of both single-and double-arm trials, we propose a single-to-double arm design to examine the superiority of the experimental treatment to the standard. The hypothesis test is formulated as
In the first (single-arm) stage, n 1 patients receive the experimental treatment, and let X 1 denote the number of responders. If X 1 ! r, the trial would continue to the second stage, where r is a prespecified threshold for futility stopping. Once the trial proceeds to the second (two-arm) stage, a total of 2n 2 patients are equally randomized to the experimental and the standard arm, and let X 2 and Y 2 denote the respective numbers of observed responses.
Denote the sample proportionsp
, and the pooled-sample proportion
At the end of stage 2, we reject H 0 if Z 4 z , where the usual Z-test statistic is
and z denotes the 100ð1ÀÞ th percentile of the standard normal distribution.
Bayesian predictive probability and futility stopping
There often exists some prior information for the standard treatment, while much less is known about the experimental treatment. We assume two different beta prior distributions for p S and p E , i.e. p S $ Betaða S , b S Þ and p E $ Betaða E , b E Þ. The parameters a E and b E typically take small values to represent a noninformative prior on p E . For simplicity, we set a E ¼ b E ¼ 1, although a more realistic prior conditional on a S and b S , such as a E ¼ 2a S =ða S þ b S Þ and b E ¼ 2b S =ða S þ b S Þ, can be used. To determine the threshold value r in the first stage, we define the predictive probability (PP) of rejecting the null hypothesis at the end of stage 2 given observing x 1 responses among the first n 1 patients in the experimental arm
where the posterior predictive distributions are beta-binomial in the form of
with Bða, bÞ ¼ ÀðaÞÀðbÞ=Àða þ bÞ. For fixed values of n 1 and n 2 , we can obtain r as the smallest integer satisfying
where c L is the minimum required posterior predictive rejection probability. Typically, we specify c L to be a small number such as 0.10 or 0.20. At the end of stage 1, if we observe fewer than r responders, we would terminate the trial since the PP of rejecting the null in the future is so low, i.e. less than c L .
Rejection probability function
To find the values of n 1 and n 2 that can maintain the power of the design, we define a rejection probability under the design parameters ðn 1 , n 2 , rÞ
where bðx; n, pÞ is the binomial probability mass function. For notational simplicity, we abbreviate hð p E , p S jn 1 , n 2 , r, Þ as h r ð p E , p S Þ. To alleviate computational burden, we approximate the rejection probability through a normal distribution
and ÈðÁÞ denotes the cumulative distribution function of the standard normal distribution. One important property of h r ð p E , p S Þ is that for a fixed value of p S , it is a monotonic increasing function of p E . Intuitively, given a fixed standard response rate, the larger the experimental response rate, the higher the chance of rejecting the null and declaring the drug promising. As an illustration, Figure 1 presents the monotonic increasing relationship between h r ð p E , p S Þ and p E when fixing p S ¼ 0:20 for a design with parameters ðn 1 , n 2 , rÞ ¼ ð20, 44, 5Þ and the type I error rate ¼ 0:10. Another feature of h r ð p E , p S Þ is that for fixed p E and p S , the larger the value of r, the smaller the rejection probability. This indicates a reduction in the rejection probability when a more stringent futility stopping rule is enforced on the experimental arm.
The rejection probability h r ð p E , p S Þ can be interpreted as the type I error rate under H 0 : p E p S and as power under H 1 : p E 4 p S . Because h r ð p E , p S Þ is a monotonic increasing function of p E for a fixed p S , when p E 5 p S ¼ , we have h r ð p E , Þ 5 h r ð, Þ. Hence, to control the type I error rate, it is sufficient to examine the values of h r ð p E , p S Þ evaluated at p E ¼ p S ¼ , for different values of . On the other hand, the rejection probability h r ð þ , Þ can be interpreted as power. Traditionally, we fix ¼ p null to maintain the power of a design. For a single-to-double arm design, we study the pattern of how power changes as we allow to vary.
A single-to-double arm design tends to have a smaller type I error rate for smaller values of . As an example, we compare such a design without early stopping (r ¼ 0) and that with early stopping (r > 0). For r ¼ 0, it is expected that h 0 ð, Þ would be close to , regardless of the value of . When r > 0, the type I error rate is reduced, particularly for the range of smaller values of , because the single-arm futility stopping threshold tends to screen out treatments with a low response rate. As shown in Figure 2 , the reduction of the type I error rate appears more evident in the range of 0 5 5 p null ¼ 0:2. Due to the small sample size of a phase II trial, the type I error rate is not controlled within the nominal level exactly, as the Z-test is established in an asymptotic sense. For illustration, the dot-dashed line represents a standard two-arm design with 1000 samples in each arm, and its type I error rates are very close to the nominal level.
Robustness of detectable treatment difference
Due to the power reduction induced by the futility stopping rule, it might be insufficient to maintain the power value h r ð þ , Þ only at ¼ p null . In contrast, we adopt a stochastic approach to maintaining power. We define a new concept called the detectable treatment difference
which is the smallest treatment difference that can be detected while maintaining power at 1 À . Since h r ð p E , p S Þ is a monotonic increasing function of p E for a fixed p S , Áð p S Þ represents the treatment difference that a design is able to detect with at least 1 À power. Figure 3 shows the detectable treatment difference for four different designs: the first design (solid line) is a single-to-double arm scheme without early stopping, which maintains power 0.80 when ð p E , p S Þ ¼ ð0:20, 0:40Þ; the second and third (dashed and dot-dashed lines) are single-to-double arm designs which impose early futility stopping with r > 0 but have the same sample size as design 1, and thus both cannot maintain power of 0.80 to detect a difference of 0.20 of p E over p S when p S ¼ 0:20; design 4 (dotted line) enlarges the sample size in stage 2 from 38 to 44 so as to regain power back to 0.80. Correspondingly, Figure 4 shows the pattern of power as p S varies with a fixed treatment difference of p E À p S ¼ 0:20 under the four designs. We conclude that imposing a threshold r > 0 to the initial single-arm stage would result in a larger detectable treatment difference (and hence loss of power for the smaller detectable treatment difference of 0.20), primarily when the true value of p S is smaller than its specified value. By adding more samples in the second stage of the single-to-double arm design, power can be recovered. For design 4, the detectable treatment difference is maintained below 0.20 and power is maintained above 0.80 when p S is equal to p null ¼ 0:20. The overall effect on power at other values of p S is twofold: When p S is greater than its prespecified value p null , there is a slight power gain; when p S is smaller than p null , the power loss appears to be more prominent. From our experience, the uplifting tail where p S is close to 0 is more evident for cases when r is large. This is certainly as expected since with a larger threshold value of r more trials tend to be stopped early for futility, which implies greater loss in power. When r is relatively small, in Figure 3 , the uplifting tail to the left side of p null would appear to be ignorable. On the other hand, a larger value of stopping threshold r would induce greater loss in power when p S is close to 0. Therefore, for a single-to-double arm design, it is insufficient to maintain the power at the single specified point p S ¼ p null only, without consideration of the uncertainty regarding p S and hence the variability of power. To be conservative, instead of focusing on a single power value, it is more desirable to control the tail percentile of power or the detectable treatment difference Áð p S Þ over an assumed prior distribution of p S . Although the detectable treatment difference in Figure 3 and power in Figure 4 appear to be mirror images of each other, they are in fact conceptually different. We focus on Áð p S Þ because it is a more intuitive way of representing the range of treatment differences that a design can identify.
The uncertainty of p S calls for a more rigorous examination on the power of the single-to-double arm design. For power protection, we treat power as a stochastic variable whose randomness arises from the uncertainty of p S . More specifically, suppose that we elicit a prior distribution Betaða S , b S Þ for p S , and our goal is to control the kth percentile of the detectable treatment difference Áð p S Þ to be equal to , where the value of k (0 5 k 5 100) is typically close to 100. This ensures that with k percent probability we can maintain the detectable treatment difference at under the assumed prior distribution of p S . To achieve this goal, we can simulate samples from the prior distribution of p S , compute the detectable treatment difference for each sample, and summarize the sample percentile for Áð p S Þ. We then obtain an admissible set of ðn 1 , n 2 , rÞ such that the kth sample percentile of Áð p S Þ is equal to .
Optimality criterion and searching algorithm
Given the experimental response rate p E , the expected sample size of a single-to-double arm design is equal to n 1 þ 2n 2 PrðX 1 ! rÞ. To choose the best set of ðn 1 , n 2 , rÞ, we adopt the commonly used criterion of minimizing the ASN, which is defined as the average of the expected sample sizes under the null and alternative hypotheses, ASN¼ ðEN 0 þ EN 1 Þ=2. Chang et al. 20 used such a concept to find the optimal design in single-arm group sequential phase II trials. Rather than using the conventional approach where EN 0 and EN 1 are, respectively, defined as the expected sample sizes under p E ¼ p null and p E ¼ p null þ , we take a Bayesian approach that averages the expected sample sizes over two beta prior distributions for p E , Beta ða E 0 , b E 0 Þ and Beta ða E 1 , b E 1 Þ. Under such beta prior distributions for p E , the first stage response number X 1 follows beta-binomial distributions and the expected sample sizes can be computed as We take the beta prior of p E for computing EN 0 to be the same as that of p S , i.e. a E 0 ¼ a S , b E 0 ¼ b S . The beta prior used for computing EN 1 has the same variance as Beta ða E 0 , b E 0 Þ, but a mean shifted by , which results in the parameters
We apply a searching algorithm to find the optimal set of design parameters ðn 1 , n 2 , rÞ that minimizes the ASN. In the planning stage, we specify the type I error rate , power 1 À , the targeted treatment difference , the prior distributions of p S and p E , c L , and the percentile value k. The searching algorithm is described in detail as follows.
(1) Enumerate n 1 from 10 to N=2, where N is the sample size for a standard equal allocation two-arm design with the type I error rate and power 1 À . (2) For each n 1 , enumerate n 2 from 2 to N. (3) For each pair of n 1 and n 2 , we obtain r as the smallest integer satisfying equation (1) . (4) For each set of design parameters ðn 1 , n 2 , rÞ, we simulate a large number of samples of p S from its prior distribution Betaða S , b S Þ, compute the corresponding detectable treatment differences, and then set the kth percentile of Áð p S Þ samples as. (5) If the resulting is smaller than , we record the current parameters ðn 1 , n 2 , rÞ as being admissible, and move on to the next round of computation with n 1 þ 1. (6) Among all the admissible sets of ðn 1 , n 2 , rÞ, we select the one that yields the smallest ASN. For computational efficiency, we adopt the bisectional searching method on n 2 , i.e. by grouping steps 3 and 4 into a function with n 2 as its input and as its output. Empirically, such a function is found to be monotonic with n 2 . Hence, we can apply the bisectional searching method to find the smallest n 2 such that its associated is smaller than .
Simulation study
We carry out extensive simulation studies to assess the performance of the proposed two-stage single-to-double arm design. To understand the interplay between the design parameters and sample size, we first fix n 1 and compute n 2 and r under different specifications of the lower cutoff probability c L , the percentile parameter k, and the beta prior distribution for p S , Betaða S , b S Þ. We set p null ¼ 0:20 and the target treatment difference ¼ 0:20. The trial is designed to satisfy the type I error rate ¼ 0:10 and power 1 À ¼ 0:80. We fix n 1 ¼ 36, and compute n 2 and r for c L ¼ f0:05, 0:1, 0:15, 0:2, 0:25g, the beta prior hyperparameters ða S , b S Þ ¼ fð1:5, 6Þ, ð5, 20Þ, ð20, 80Þg, and k ¼ f75, 85, 95g, respectively. Table 1 shows the solutions of ðn 2 , rÞ and sample sizes under different trial specifications and reveals several key findings with respect to the trade-offs between futility termination, power, and sample size. First, as the beta prior distribution for p S becomes more informative, the trial would require a smaller number of patients in stage 2, and thus results in a smaller ASN. This is mainly because a more informative prior allows us to rule out the unfavorable numbers of responses more easily during the single-arm stage. Moreover, a more informative prior leads to a more concentrated distribution of the detectable treatment differences, hence requires fewer samples in stage 2 to maintain its tail percentile below . Second, a more stringent requirement on the percentile parameter k would lead to an increase in sample size, because the more robustness in terms of maintaining power, the larger the required sample size. Third, a larger probability cutoff c L typically results in a smaller sample size although the relationship might not be strictly monotonic. A larger c L corresponds to a higher futility stopping threshold r, which leads to a higher probability of early termination of the trial, and thus induces a smaller ASN. Finally, the threshold value r increases as the prior distribution of p S becomes more informative. This implies that with more information on p S , we would have more confidence in using a higher stopping boundary at the end of the first stage.
Therefore, one needs to consider the trade-offs between futility termination, power, and sample size to deliver a reasonable trial design. In general, an increase in sample size may be due to a larger k, a smaller c L , or a more dispersed prior distribution of p S . The choice of k depends on the willingness to put in additional samples to validate the treatment effectiveness with more robust power. The choice of c L depends on the degree of confidence clinicians have for the new drug being promising. The prior distribution of p S should be derived in a reasonable manner to reflect the best estimate of the variability of the standard response rate without being overly conservative.
In the second set of simulations, we allow n 1 to vary as well, and search for the optimal values of ðn 1 , n 2 , rÞ. We consider the configurations with p null ¼ f0:10, 0:20, 0:30, 0:40g and ¼ 0:20, under different beta prior distributions for p S and different values of k and c L . Due to the typical constraint on sample size in phase II trials, we set ¼ 0:10 and 0.20, which are the nominal levels commonly used for randomized phase II studies. 17, 18 In addition, we compute the approximate and exact power values when ð p E , p S Þ ¼ ð p null þ , p null Þ, as well as the exact type I error rates when ð p E , p S Þ ¼ ð p null , p null Þ. Table 2 summarizes the results for c L ¼ 0:10 and Table 3 corresponds to c L ¼ 0:20. Generally, the normal approximation approach to power calculation is accurate. The traditional approach maintains power only at the specified level of p S . When the degree of uncertainty on p S is large, we ensure the robustness of power by controlling the tail percentile of the detectable treatment difference over a prior of p S . As a result, additional samples may be required, especially for a large value of percentile k. This is also reflected by the observation that the power values at ð p E , p S Þ ¼ ð p null þ , p null Þ are larger than 1 À ¼ 0:80. When the prior distribution of p S is relatively informative, the single-arm stage of the design can effectively screen out the drug with a low response rate, and hence the potential saving in sample size due to early termination would be large. In some extreme cases, the searching algorithm may produce a zero value of r, indicating that adopting a single-to-double arm trial without futility stopping is preferred. This tends to happen more often when c L and p null are small and the prior distribution of p S is dispersed. A heuristic explanation for this phenomenon is that it would be difficult to find a nonzero threshold value r which reflects inferiority to a response rate that is already very low. On the other hand, under some rare situations where c L is relatively large (e.g. 0.20 or 0.25) and k is close to 100 (e.g. 95 or 99), the design would require a large sample size to maintain power. One possible reason could be that given the power loss induced by a large c L (and hence a large threshold r), it might be difficult to control the high tail percentile of the detectable treatment difference below . In the extreme cases, an overly large value of c L (e.g. greater than 0.5) would be unrealistic in that it leads to a high threshold value r that hampers the design power to the extent that no matter how large n 2 is, the power value can never be maintained at our specified level. We can remedy such a problem by selecting a smaller c L ; for example, we recommend c L ¼ 0:10 and k ranging from 75 to 95.
Pancreatic cancer trial
Our research is motivated by a two-stage phase II trial of a new regimen in patients with metastatic pancreatic cancer. To successfully attract and recruit a sufficient number of patients in a reasonable period of time, a singleagent trial is intended to be conducted such that all the eligible patients will receive the new regimen at the first stage. If the early stopping threshold for futility is exceeded by the end of stage 1, subsequent patients will be enrolled into the second stage. At stage 2, eligible patients are randomized to receive either the new regimen or the standard-dose intravenous therapy gemcitabine. The final analysis is to be performed to examine the superiority of the new regimen compared with the control. To meet the aforementioned requirements as well as to fully utilize the advantages of single-and double-arm comparisons, we apply the proposed two-stage single-to-double arm design to control the type I error rate ¼ 0:10 and achieve a robust power value of 1 À ¼ 0:80 at a targeted treatment difference ¼ 0:20 with p null ¼ 0:20. We set the lower cutoff for the PP at the end of the first stage c L ¼ 0:20, and set the percentile parameter k ¼ 95, i.e. with 95% probability we can maintain the detectable treatment difference at 0.20 under the assumed prior distribution of p S . If the historical data are rich for the standard treatment, or if the clinical investigators have a reliable estimate for the standard response rate p S , an informative prior can be used. For illustration, we assume a prior distribution Betað20, 80Þ for p S . Based on the proposed method, the optimal design parameters ðn 1 , n 2 , rÞ are computed to be (21, 46, 5) . During the trial conduct, we enroll the first 21 patients to the experimental arm in stage 1. If there are five responders or more, the trial proceeds to the second stage, in which 46 patients are allocated to each of the experimental and standard arms. At the end of stage 2, a hypothesis test is performed to evaluate the efficacy difference between the two treatments. On the other hand, when the amount of historical information on the standard drug is limited, we may assume a relatively less informative prior for p S , for example p S $ Betað2, 8Þ, and the single-to-double arm design would then yield the optimal design parameters ðn 1 , n 2 , rÞ to be (12, 51, 2) . We calculate the expected sample sizes of our proposed designs and compare them with those of other existing designs. Table 4 shows the parameters and sample sizes for the various designs under comparison. To deliver a uniform framework of comparison on the expected sample sizes across various methods, EN 0 and EN 1 are, respectively, defined as the expected sample size under p E ¼ p null and under p E ¼ p null þ , and ASN is the average of these two quantities.
We also explore Simon's two-stage design 1 under the hypothesis test H 0 : p E p null versus H 1 : p E 4 p null þ , where p null is the maximum clinically uninteresting response rate and p null þ is our clinically desired response rate. When p E falls in between p null and p null þ , we are indifferent toward the effectiveness of the drug. Stage 1 and stage 2 enroll n 1 and n 2 subjects, respectively, with a futility stopping criterion r between the two stages. The design parameters are calibrated such that the probability of rejecting the null equals to and 1 À when p E ¼ p null and p E ¼ p null þ , respectively. Simon's two-stage design can be calibrated according to two optimality criteria: One is called the ''optimal'' design, where the expected sample size under the null is minimized, and the other is called the ''minimax'' design, where the total sample size n 1 þ n 2 is minimized. For a single-arm trial, Simon's optimal design has the design parameters ðn 1 , n 2 , rÞ ¼ ð12, 13, 3Þ and ðEN 0 , EN 1 , ASNÞ ¼ ð17:7, 23:9, 20:8Þ. Simon's minimax design leads to the design parameters ðn 1 , n 2 , rÞ ¼ ð14, 10, 3Þ and ðEN 0 , EN 1 , ASNÞ ¼ ð19:5, 23:6, 21:5Þ. Simon's two-stage design has a much smaller sample size than other designs under comparison. It is most efficient when we have an accurate guess of p S , whereas when there is substantial uncertainty about p S , it would be more objective to conduct a double-arm comparison. As a further comparison with Simon's design when there is uncertainty on p S , we set k ¼ 50 in our proposed method and assume p S $ Betað2, 8Þ, which leads to the design parameters ðn 1 , n 2 , rÞ ¼ ð13, 41, 2Þ and ðEN 0 , EN 1 , ASNÞ ¼ ð75:8, 94:0, 84:9Þ. We sample p S from Betað2, 8Þ, and compute the power for each sample, i.e. the probability of declaring the drug promising when p E ¼ p S þ 0:2 (capped below one). Table 5 summarizes the sample percentiles of power under the two designs. Although Simon's design involves no control arm, and conducts a different hypothesis test from that of the single-to-double arm design, the 50th percentile of power for Simon's design also falls around the target power 0.80. Nevertheless, Simon's design becomes severely underpowered or overpowered for lower and upper percentiles of power, whereas the distribution of power for the single-to-double arm design is more centered around 0.80, indicating its power is more robust against the uncertainty of p S .
We also compare our design to the standard two-arm design where patients are equally randomized. For a head-tohead comparison, we apply our stochastic power approach that aims to control the 95th percentile of the detectable treatment difference to a standard two-arm trial, i.e. enforcing n 1 ¼ 0 in our design. Under such a stochastic approach, a two-arm design that assumes a Betað20, 80Þ prior for p S would require 52 patients in each arm, and if a Betað2, 8Þ prior is assumed instead, it would require 54 patients. We also investigate the sample size under the commonly used deterministic power approach, which requires 46 patients in each arm to maintain the rejection probability at 1 À when ð p S , p E Þ ¼ ð p null , p null þ Þ. This indicates that controlling the 95th percentile of the detectable treatment difference is more conservative and requires more samples than the deterministic power approach. Compared with these standard two-arm designs, our design has a smaller ASN but a larger maximum sample size, i.e. n 1 þ 2n 2 . This is expected because the possibility of sample size saving in case of early termination comes at the cost of a larger maximum sample size. In addition, we include further comparisons with two existing adaptive designs (Storer 14 and Thall et al. 19 ), under the same constraints on the type I error rate and power. Similar to the proposed method, these two adaptive designs consist of two stages, incorporate futility stopping at the end of stage 1, and test the same hypothesis as ours at the end of stage 2. In Storer's design, a total of 2ðn 1 þ n 2 Þ patients are equally allocated to the two arms under comparison.
14 After the experimental arm accumulates n 1 patients, its response rate is assessed, which essentially tests the hypothesis H 0 : p E p null versus H 1 : p E 4 p null þ . The trial would only proceed if the null is rejected, and at the end of stage 2, a Z-test is conducted to compare the experimental treatment with the control. In the design by Thall et al., 19 a two-stage randomized trial is carried out that allows early stopping for futility. At the end of stage 1, where n 1 patients are assigned to each arm, an interim test is conducted, comparing the difference between the response numbers in the two arms to a futility stopping boundary. Both adaptive designs use ASN as the criterion to optimize their design parameters. It is worth emphasizing that our design differs from these two designs in the trial structure, i.e. ours has a lead-in single-arm stage whereas these two designs start randomization right from the beginning of the trial, which explains why our design has a smaller ASN than the two existing designs.
Discussion
Although single-arm studies remain to be a popular choice for phase II trials due to ease of conduct and smaller sample size, it is undesirable to carry the investigation directly to a large-scale phase III study after a phase II study with no control arm, especially when the degree of uncertainty on p S is large. To build a middle ground and provide a more objective comparison before proceeding to phase III development, we propose to seamlessly combine single-and double-arm studies in one trial. Nevertheless, this may induce potential loss in power if one only aims to maintain power at ð p S , p E Þ ¼ ð p null , p null þ Þ without considering the variability of p S . By treating power as a stochastic quantity, our approach aims at controlling the tail percentile of the detectable treatment difference. Compared with running independent and separate phase IIa and IIb trials, our design would eliminate the gap time and save sample size by pooling the data together from the two stages.
Since patients from both single-and double-arm stages are pooled together for final decisions, investigators of the trial need to be precautious about the potential bias incurred during the patient accrual in the single-arm stage and should seek to ensure a balanced allocation of patients' prognostic factors not only in two arms, but also across the two stages. One practical concern is the potential selection bias during the single-arm stage of the design, in which investigators might be inclined to select and enroll subjects with better prognostic factors. The potential selection bias might result in an increased risk of false positive results as patients from both the single-and doublearm stages are pooled together for final decisions. It is crucial that the patients in the single-arm stage are ''indistinguishable'' from the remaining patients in the trial. To mitigate the selection bias, we can implement a double-blinding scheme, where both investigators and patients are blinded from knowing not only the identity of treatment assignment, but also the identity of stage assignment, i.e. whether a patient is assigned to the single-arm stage or the double-arm stage. Under such a scheme, the investigators would be unaware of either the existence of the single-arm stage, or the fact that data from the single-arm stage are to be used for the final decision. We introduce a new concept called the detectable treatment difference, which is the smallest treatment difference that can be detected while maintaining power at 1 À . Similarly, we can define a detectable treatment ratio, which is equal to inffp E : h r ð p E , p S Þ ! 1 À \ p E 4 p S g=p S . Other similar notions may be derived in an analogous manner for normal and time-to-event endpoints. In addition, we adopt a new stochastic approach to maintaining the robustness of power specifically for the single-to-double arm design. Compared with the traditional approach, the advantage of a stochastic approach is evident as the number of design parameters increases and the relationship between a design's operating characteristics and its parameters can no longer be straightforwardly defined. For a standard two-arm design, the power becomes larger when the total sample size increases; this however might not be the case for a single-to-double arm design. The stochastic approach is particularly useful for providing a unified framework under which we are able to calibrate multiple design parameters.
